Transchem Ltd (TRANSCHEM) — shareholding pattern, promoter holding, financials and share price
About Transchem Ltd (TRANSCHEM)
Transchem Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as TRANSCHEM and on the BSE under scrip code 500422. Its ISIN is INE019B01010.
Incorporated in 1976, Transchem Ltd is engaged in the business of Mushroom production and processing.
Transchem Limited initially engaged in chemicals and pharmaceuticals, transitioned toward mushroom production, operating a 100% Export Oriented Unit in Pune. However, this plant became non-operational due to changes in the horticulture industry.
The company manufactures bulk drugs primarily in Maharashtra, with frusemide, fenbendazole, and albendazole as key products.
Listed peers in Pharmaceuticals: Albert David Ltd, Aptus Pharma Ltd, Astal Laboratories Ltd, Valiant Laboratories Ltd, Medicamen Biotech Ltd, Medico Remedies Ltd.
Valuation & Returns
10 Jul 2026At ₹327.85 a share on 10 Jul 2026, Transchem Ltd (TRANSCHEM) was valued at a price-to-earnings ratio of 93.54x against an industry P/E of 36.41x and a price-to-book of 5.06x on a book value of ₹64.8 per share as of Mar 2025. Solomo computes return on equity of 5.41% and return on capital employed of 7.07% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 93.54x
- Industry P/E
- 36.41x
- P/B
- 5.06x
- EPS (TTM)
- ₹3.5
- Book value / share
- ₹64.8
- ROE
- 5.41%
- ROCE
- 7.07%
- ROA
- 5.38%
- Debt / equity
- 0x
- Dividend yield
- 0%
- 52-week range
- ₹38.31 – ₹356.15
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Transchem Ltd (TRANSCHEM) reported net profit of ₹4.3 crore and earnings per share of ₹3.51. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, net profit ₹2.09 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | -0.2 | 0 | 0.34 | 2.57 | 0 |
| Net profit (₹ cr) | 2.87 | 1.24 | 4.2 | 5.23 | 4.3 |
| EPS (₹) | 2.34 | 1.01 | 3.43 | 4.27 | 3.51 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | - | - | - | 541.46% |
| Profit growth | 68.87% | 66.41% | 22.14% | 24.52% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 56.45% of Transchem Ltd (TRANSCHEM) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.03% and domestic institutional investors (DII) hold 0.01%. Market capitalisation was ₹401 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2001.
Largest disclosed public shareholders in Jun 2026: Smit Capital Services Private Limited 11.02%, Firstcorp International Limited 4.49%, LLP 1.4%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 56.45% | - | 0.03% | 0.01% | 43.55% |
| Mar 2026 | 56.45% | - | 0.03% | 0.01% | 43.55% |
| Dec 2025 | 56.45% | - | 0.03% | 0.01% | 43.55% |
| Sep 2025 | 56.45% | - | 0.03% | 0.01% | 43.55% |
| Jun 2025 | 56.45% | - | 0.03% | 0.01% | 43.55% |
| Mar 2025 | 56.45% | - | 0.03% | 0.01% | 43.55% |
| Dec 2024 | 51.68% | - | 0.03% | 0.01% | 48.32% |
| Sep 2024 | 51.68% | - | 0.03% | 0.01% | 48.32% |